Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and SCLC; vafidemstat, its CNS product, is in Phase IIa trials in MS, AD and aggression. Newer asset ORY-3001 is being developed for certain orphan indications.
Oryzon’s expertise lies in developing small molecule inhibitors for epigenetic targets. The company has a total of five Phase II studies ongoing with its two lead assets iadademstat (formerly ORY-1001, a specific LSD1 inhibitor) and vafidemstat (formerly ORY-2001, a dual LSD1/MAOB inhibitor), which are all expected to have more preliminary data readouts in 2019. In April 2019, the first data were published from a Phase IIa trial with vafidemstat (ORY-2001) in aggressiveness. Patients with several neuropsychiatric disorders were enrolled in the trial and the first efficacy data in borderline personality disorder cohort showed that all primary and secondary endpoints were met. Two other Phase IIa trials with vafidemstat in AD and MS and another two Phase IIa trials in AML and SCLC with the lead oncology product iadademstat (ORY-1001) are all expected to deliver data in late H219.
Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.